News

Weslie Janeway - investor, philanthropist, and scientist - joins bit.bio's Board of Directors.

This collaboration will combine the Mekonos novel ex vivo delivery platform with bit.bio’s opti-ox precision cellular reprogrammin...

Our CEO and host Jim Cornall have a wide ranging discussion around cell programming, the ethics and use of human cells in research...

Our VP of R&D Manos Metzakopian writes in Innovations in Pharmaceutical Technology about novel technologies that enable researcher...

Device that could restore limb function to amputees and others who have lost the use of their arms or legs uses opti-ox reprogramm...

Our CEO was interviewed in this piece about the barriers and opportunities for scaling companies in the UK.

Statement from our CFO on the situation concerning SVB.

Featured in Technology Dispatch, bit.bio SVP of Technical Operations & Cell Manufacturing, Kathryn Golden, shares her insights int...